← board
CDT
distress 8/10 · high distress / dilution risk$3.29-3%today-99% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
+106%
Price & events
-90.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
+826.8%
1W
+186.1%
1M
+11.1%
3M
-89.1%
6M
-99.2%
1Y
-100.0%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $20.76M
- Volume
- 21.53K
- 52 Week Range
- $0.31 – $472
- Total Shares
- 6.31M
- Float Shares
- 396.88K
- Short %
- 6.59%
- % Held by Insiders
- 35.09%
- % Held by Institutions
- 0.21%
- RVOL
- 0.00x
- Beta
- 1.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-12-29partnershipEngaged NJS for advisory and business development services to support out-licensing of asset portfolio.SEC 8-K
- 2025-12-28partnershipAZD1656 · Consulting agreement with Thesprogen to evaluate pre-clinical data on AZD1656 and devise strategies.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 6,310,778 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.